HOME >> BIOLOGY >> NEWS
Major new UNC-based drinking water study suggests pregnancy fears may be overstated

CHAPEL HILL Fears that chemical byproducts resulting from purifying drinking water with chlorine boost the chances that pregnant women will miscarry were not supported by the results of a major new study. If such threats exist at all, which is uncertain, they likely are modest, it concludes.

The national study, directed by University of North Carolina at Chapel Hill scientists, contrasts with earlier, less detailed work done in Northern California and published in 1998. That research suggested an association between byproducts known as trihalomethanes and loss of pregnancy.

"We think our new work should be an important contribution to policy studies," said principal investigator Dr. David A. Savitz of the UNC School of Public Health. "While it is not the final answer, what we found is largely reassuring relative to what had come before.

"The vast majority of the U.S. population is living with these exposures to drinking water byproducts," Savitz said. "If they clearly increased women's miscarriage rates, that would be a very big, very expensive problem to solve. Reducing exposure would be quite expensive for the water utilities and ultimately their customers."

The methods used in the new work make it the most ambitious and sophisticated study ever done on this issue, he said.

Savitz, Cary C. Boshamer distinguished professor and chair of epidemiology, and colleagues released a report on the investigation today (July 29). The American Water Works Association Research Foundation, a non-partisan, non-profit research group, sponsored it.

Others involved include Dr. Philip C. Singer, professor of environmental sciences and engineering and co-principal investigator, and Drs. Katherine E. Hartmann of obstetrics and gynecology and epidemiology, Amy H. Herring of biostatistics and Howard S. Weinberg of environmental sciences and engineering.

The scientists selected and repeatedly tested three properly functioning wate
'"/>

Contact: David Williamson
rdtokids@email.unc.edu
919-962-8596
University of North Carolina at Chapel Hill
29-Jul-2005


Page: 1 2 3

Related biology news :

1. Major breakthrough in understanding how HIV interferes with infected cell division
2. Major study predicts grim future for Europes seas
3. Major genetic study identifies clearest link yet to obesity risk
4. Major gene study uncovers secrets of leukemia
5. Major society publisher announces support for public access to scientific literature
6. Major link in brain-obesity puzzle found
7. Major Wellcome Trust award to take science from the bench to the bedside
8. Major breakthrough in the mechanism of myelin formation
9. Major new osteoporosis study to recruit people in Orkney
10. Major genetic risk factor found for prostate cancer
11. Major report on tigers to be released Thursday at National Zoo

Post Your Comments:
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi ... Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in ... core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... Costello ... new levee system to protect the Orange County, Texas area from future storm ... multi-firm design team in determining several potential levee alignment alternatives for providing protection, Costello ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2
Cached News: